This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Echo Therapeutics Presents Positive Clinical Trial Results Of The Symphony® TCGM System At The American Diabetes Association's 72nd Scientific Sessions

Stocks in this article: ECTE

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System.  The data were presented during an oral presentation session on Friday, June 8 at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, PA.

The presentation [ADA abstract 007-OR], entitled "Transdermal Continuous Glucose Monitoring Following Skin Permeation," by Wayne Menzie, Echo's Director of Technology and Clinical Development, provided data from twenty (20) adult subjects with type 1 or type 2 diabetes whose glucose levels were monitored continuously for 24 hours.  The key findings include:

  • Symphony successfully monitors the broad range of blood glucose values seen in people with diabetes.
  • Using over 2,600 Symphony tCGM glucose readings paired with reference blood glucose measurements, the Mean Absolute Relative Difference (MARD) was 12.6% and the Median Absolute Relative Difference (MedianARD) was 11.8%.  The overwhelming majority of sensors had a MARD between 8.0% and 15.9% with an overall MARD of 11.3% and a MedianARD of 10.7%.
  • The Continuous Glucose-Error Grid analysis (CG-EGA) showed that 94.4% of the readings were clinically accurate and 2.5% were benign errors with a combined A+B of 96.9%.
  • Values for blood glucose measurements ranged from 42 to 333 mg/dL.  Most of the study subjects experienced a large degree of glycemic variability with twelve (12) having a standard deviation of all blood glucose measurements of greater than 40 mg/dL and only four (4) subjects less than 30 mg/dL.
  • An important component of continuous glucose meter performance, the R deviation is a measurement of rate accuracy that examines the difference between the rate of the reference blood glucose measurements and the calculated rate of the CGM over that same time.  In this study, 84.7% of the calculated CGM rates were within + or - 1 mg/dL/min of the reference rate and 96.8% were within + or - 2 mg/dL/min. 

Following the oral presentation, Echo hosted a panel discussion on hospital-based glucose control with Key Opinion Leaders (KOLs) in glycemic control.   Anthony Furnary, M.D. (Starr-Wood Cardiac Group, Portland, OR), Jeffrey Joseph, D.O. ( Thomas Jefferson University Hospital, Philadelphia, PA), Stanley Nasraway, M.D. (Tufts Surgical Center, Boston, MA), and Eileen Donnelly, R.N., B.S.N. ( Thomas Jefferson University Hospital, Philadelphia, PA) discussed the need for continuous glucose monitoring in hospitals.

"We are extremely pleased with the outcome of the study and our Research & Development team's progress on Symphony.  We believe that Symphony successfully monitors glucose in the challenging diabetes population who experience rapid rates of change and a broad range of glucose levels," said Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "Additionally, the KOLs at our symposium confirmed the major need for hospital-based continuous glucose monitoring to better control glucose levels in critically ill patients.  We value this opportunity for engagement with the medical community to share the Symphony diabetes and critical care data with experts in the field."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs